Dr David Croucher
David completed his undergraduate studies and PhD research at the University of Wollongong, followed by a post-doctoral position at the Garvan Institute, all of which focused on the role that individual proteins play in the behaviour of cancer cells. Pursuing the idea that these cancer-related proteins do not act in isolation, but are actually embedded within dynamic networks, David undertook a second post-doctoral position at Systems Biology Ireland in University College Dublin.
After establishing an independent research group at Systems Biology Ireland, David received a Future Research Leader grant from Cancer Institute NSW and has now returned to the Garvan Institute as head of the Network Biology group. The focus of his research group is the investigation of network level aberrations induced by oncogenes and oncogenic mutations, ultimately aiming to elucidate how altered network behaviour leads to therapeutic resistance.
In the NewsNew technique to delve further into cancer cell biology - Jul 20, 2016
Garvan researchers benefit from Cancer Institute NSW equipment funding - Aug 31, 2015
Dr David Croucher announced as winner of the 2015 Young Garvan Award - Jul 20, 2015
Awards and Honours
2015 - Pilot and Seed Funding, Sydney Catalyst
2015 - Research Equipment Grant, Cancer Institute NSW
2014 - Future Research Leader Fellowship, Cancer Institute NSW
2013 - Young Leader of the Year (Finalist), Irish Laboratory Awards
2013 - Pilot Grant, Breast Cancer Campaign UK
2012 - Starting Investigator Research Grant, Science Foundation Ireland and Marie Curie Actions COFUND
2007 - Cancer Institute Early Career Development Fellowship, Cancer Institute NSW
2006 - Premiers Award for Outstanding Cancer Research Scholar, Cancer Institute NSW
2005 - Cancer Institute Research Scholar Award, Cancer Institute NSW
2004 - International Society for Fibrinolysis and Proteolysis Special Achievement Award - 17th International Congress on Fibrinolysis and Proteolysis, Melbourne, Victoria
2003 - Bachelor of Biotechnology (1st Class Honours) - University of Wollongong, Australia
Croucher DR#, Iconomou M, Hastings JF, Kennedy SP, Han JZR, Shearer R, McKenna J, Wan A, Lau J, Aparicio S, Saunders DN#. (2016) Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers. Science Signaling, 9(436), ra69.
Rogers S, Fey D, McCloy RA, Parker BL, Mitchell NJ,Payne RJ, Daly RJ, James DE, Watkins DN, Croucher DR, Burgess A. (2016) PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. Journal of Cell Science, 129(7):1340-1354.
EramiZ*, Herrmann D*, Warren SC, NobisM, McGhee EJ, Lucas M, Leung W, Reischmann N, Mrowinska A, Schwarz J, Kadir S, Conway JRW, Vennin C, Karim SA, Campbell AD, Gallego-Ortega D, Magenau A, Murphy KJ, Ridgway RA, LawAM, Walters SN, Grey ST, Croucher DR, Zhang L, Herzog H, Hardeman EC, Gunning PW, Ormandy CJ, Jeffry Evans TR, Strathdee D, Sansom , Morton JP, Anderson KI*, Timpson*. (2016) Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease and drug-dependent dynamic regulation of cell-cell junctions in live tissue. Cell Reports, 14(1), 152-167.
Fey D, Kolch W, Kholodenko BN, Croucher DR. (2016) Cell Systems Call – Principles in Systems Biology, No. 1. ‘Signaling Pathway Models as Biomarkers’. Cell Systems, 2(1), 2-4.
Fey D, Halasz M, Dreidax D, Kennedy SP, Hastings JF, Rauch N, Garcia Munoz A, Pilkington R, Fischer M, Westermann F, Kolch W, Kholodenko BN, CroucherDR. (2015) Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Science Signaling, 8(408), ra130.
Duffy FJ, Devocelle M, CroucherDR, Shields DC (2014). Computational Survey of Peptides Derived from Disulphide-Bonded Protein Loops That May Serve as Mediators of Protein-Protein Interactions. BMC Bioinformatics, 15 (1), 305.
Freeman R, Niego B, CroucherDR, Ostergaard Pedersen L, Medcalf RL. (2014) t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood brain barrier model under normoxic and ischaemic conditions. Brain Research, 1565:63-73.
Zheng Y, Zhang C, Croucher DR, Soliman MA, Bagshaw R, Pasculescu A, St-Denis N, Taylor L, Tate SA, Hardy RW, Colwill K, Dennis JW, Dai AY, Gingras A, Daly RJ, Pawson T (2013). Temporal regulation of EGF signaling networks by the scaffold protein Shc1. Nature, 499(7457): 166-171.
Croucher DR, Hochgräfe F, Zhang L, Liu L, Lyons RJ, Rickwood D, Tactacan CM, Browne BC, Ali N, Chan H, Shearer RF, Gallego-Ortega D, Saunders DN, Swarbrick A, Daly RJ (2013). Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway. Cancer Research, 73(6): 1969-1980.
Ortiz Padilla C, Browne BC, Hochgräfe F, Caldon CE, Lyons RJ, Croucher DR, Rickwood D, Brummer T, Daly RJ (2013). Functional characterization of cancer-associated Gab1 mutations. Oncogene, 32(21): 2696-2702.
Fey D, Croucher DR, Kolch W, Kholodenko BN. (2012) Crosstalk and signalling switches in mitogen-activated protein kinase cascades. Frontiers in Physiology, 3:355.
Nguyen LK*, Matallanas D*, Croucher DR*, von Kriegsheim A*, Kholodenko BN (2012). Signalling by protein phosphatases and drug development: a systems-centred view. FEBS Journal, 280(2):751-65. *These authors all contributed equally
Cochran BJ, Croucher DR, Lobov S, Saunders DN, Ranson M (2011). Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of serpinE1 and serpinB2 in cancer. Journal of Biological Chemistry, 286(27):24467-75.
Hochgräfe F, Zhang L, O’Toole S, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ (2010). Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Research, 70(22): 9391-401.
Lee JA, Croucher DR, Ranson M (2010). Differential endocytosis of tissue plasminogen activator by plasminogen activator inhibitors type-1 and 2 on human peripheral blood monocytes. Thrombosis and Haemostasis, 104(6): 1133-42.
Croucher DR, Rickwood D, Tactacan CM, Musgrove EA, Daly RJ (2010). Cortactin modulates RhoA activation and expression of Cip/Kip cyclin dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells. Molecular and Cellular Biology, 30(21): 5057-70.
Abdipranoto A, Park JS, Croucher DR, Daniel J, Henshall S, Galbraith S, Mervin K, Vissel B. (2009) Activin A Is Essential for Neurogenesis Following Neurodegeneration. Stem Cells. 27(6):1330-1346.
Samson AL, Nevin ST, Croucher D, Niego B, Daniel PB, Weiss TW, Moreno E, Monard D, Lawrence DA, Medcalf RL. (2008) Tissue-type plasminogen activator requires a co-receptor to enhance N-Methyl-D-Aspartate receptor function. Journal of Neurochemistry. 107(4):1091-1101.
Cao XR, Lill NL, Boase N, Shi PP, Croucher DR, Shan H, Qu J, Sweezer EM, Place T, Kirby PA, Daly RJ, Kumar S, Yang B. (2008) Nedd4 controls animal growth by regulating IGF-I signaling. Science Signaling. 1(38):ra5.
Croucher DR, Saunders DN, Lobov S, Ranson M. (2008) Revisiting the Biological Roles of PAI-2 (SerpinB2) in Cancer. Nature Reviews Cancer. 8(7):535-45.
Croucher DR, Saunders DN, Stillfried GE, Ranson M. (2007) A Structural Basis for Differential Cell Signaling by PAI-1 and PAI-2 in Breast Cancer cells. Biochemical Journal. 408(2):203-10.
Croucher D, Saunders DN, Ranson M. (2006) The PAI-2:uPA Complex: A New Ligand for the Lipoprotein Receptor-Related Protein (LRP). Journal of Biological Chemistry. 281(15):10206-10213.